Drug Trial Radar · NCT03911401
Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Jan 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
251
Actual
Start
May 7, 2019
Primary completion
Dec 13, 2019
Study completion Dec 13, 2019
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.Otsuka
- Sponsor type
- Industry
- First posted
- Apr 11, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years, up to 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To demonstrate the superiority of the investigational medicinal product (IMP; 0.3% OPA-15406 ointment, 1% OPA-15406 ointment, or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in Investigator's Global Assessment (IGA) at Week 4 as the primary endpoint in pediatric patients with Atopic Dermatitis (AD).
Conditions
- Atopic Dermatitis
Interventions
0.3% OPA-15406Drug
Twice daily
1% OPA-15406Drug
Twice daily
PlacebosDrug
Twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Responder Rate of Investigator's Global Assesment (IGA) of Disease SeverityTime frame: At Week 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kato Dermatology Clinic
Sapporo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.